Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cofstop is an over-the-counter (OTC) oral syrup developed and marketed by Ryvis Pharma, a Canadian pharmaceutical company specializing in generic and OTC medications. It is indicated for the symptomatic relief of cough and upper respiratory symptoms associated with conditions such as the common cold or respiratory tract infections. As a generic formulation, Cofstop is part of Ryvis Pharma's 'STOP' product line, which focuses on common ailment relief. While the specific active ingredients are not detailed in the company's general product listing, such syrups typically utilize small molecule antitussives, expectorants, or decongestants to alleviate respiratory distress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cofstop.